AnGes MG Inc. And Seikagaku To Dissolve Joint Development Agreement For NFkB Decoy-Oligo-Based Intraarticular Injection
Tokyo, Feb 6, 2006 (JCN) - AnGes MG and Seikagaku jointly announced on February 3 that they have agreed to dissolve their agreement on joint development of NF-kappa B decoy oligodeoxynucleotide (NFkB decoy-oligo).